159 related articles for article (PubMed ID: 18687302)
1. Cancer immunotherapeutic effects of novel CpG ODN in murine tumor model.
Cho HC; Kim BH; Kim K; Park JY; Chang JH; Kim SK
Int Immunopharmacol; 2008 Oct; 8(10):1401-7. PubMed ID: 18687302
[TBL] [Abstract][Full Text] [Related]
2. Screening of novel immunostimulatory CpG ODNs and their anti-leukemic effects as immunoadjuvants of tumor vaccines in murine acute lymphoblastic leukemia.
Wang J; Zhang W; He A; Zhao W; Cao X
Oncol Rep; 2011 Feb; 25(2):519-29. PubMed ID: 21165566
[TBL] [Abstract][Full Text] [Related]
3. CpG-ODN-based immunotherapy is effective in controlling the growth of metastasized tumor cells.
Kim HA; Ko HM; Ju HW; Kim KJ; Roh SG; Lee HK; Im SY
Cancer Lett; 2009 Feb; 274(1):160-4. PubMed ID: 18952369
[TBL] [Abstract][Full Text] [Related]
4. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA.
Ballas ZK; Rasmussen WL; Krieg AM
J Immunol; 1996 Sep; 157(5):1840-5. PubMed ID: 8757300
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo effects of CpG-Oligodeoxynucleotides (CpG-ODN) on murine transitional cell carcinoma and on the native murine urinary bladder wall.
Olbert PJ; Schrader AJ; Simon C; Dalpke A; Barth P; Hofmann R; Hegele A
Anticancer Res; 2009 Jun; 29(6):2067-76. PubMed ID: 19528466
[TBL] [Abstract][Full Text] [Related]
6. An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen.
Wakita D; Chamoto K; Zhang Y; Narita Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T
Int Immunol; 2006 Mar; 18(3):425-34. PubMed ID: 16415100
[TBL] [Abstract][Full Text] [Related]
7. Antimetastatic effect of CpG DNA mediated by type I IFN.
Hafner M; Zawatzky R; Hirtreiter C; Buurman WA; Echtenacher B; Hehlgans T; Männel DN
Cancer Res; 2001 Jul; 61(14):5523-8. PubMed ID: 11454702
[TBL] [Abstract][Full Text] [Related]
8. CpG oligodeoxynucleotide-induced immunity prevents growth of germinal center-derived B lymphoma cells.
Ponzio NM; Cutro S; Hu J; Marzouk A; Marshall JD
Int Immunopharmacol; 2006 Dec; 6(13-14):2057-68. PubMed ID: 17161362
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-21 triggers both cellular and humoral immune responses leading to therapeutic antitumor effects against head and neck squamous cell carcinoma.
Nakano H; Kishida T; Asada H; Shin-Ya M; Shinomiya T; Imanishi J; Shimada T; Nakai S; Takeuchi M; Hisa Y; Mazda O
J Gene Med; 2006 Jan; 8(1):90-9. PubMed ID: 16097036
[TBL] [Abstract][Full Text] [Related]
10. Effective CpG immunotherapy of breast carcinoma prevents but fails to eradicate established brain metastasis.
Xiong Z; Gharagozlou S; Vengco I; Chen W; Ohlfest JR
Clin Cancer Res; 2008 Sep; 14(17):5484-93. PubMed ID: 18765540
[TBL] [Abstract][Full Text] [Related]
11. Eradication of ovarian tumor xenografts by locoregional administration of targeted immunotherapy.
De Cesare M; Calcaterra C; Pratesi G; Gatti L; Zunino F; Mènard S; Balsari A
Clin Cancer Res; 2008 Sep; 14(17):5512-8. PubMed ID: 18765543
[TBL] [Abstract][Full Text] [Related]
12. Role of invariant NK T lymphocytes in immune responses to CpG oligodeoxynucleotides.
Paget C; Bialecki E; Fontaine J; Vendeville C; Mallevaey T; Faveeuw C; Trottein F
J Immunol; 2009 Feb; 182(4):1846-53. PubMed ID: 19201836
[TBL] [Abstract][Full Text] [Related]
13. NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma.
Moga E; Alvarez E; Cantó E; Vidal S; Rodríguez-Sánchez JL; Sierra J; Briones J
Exp Hematol; 2008 Jan; 36(1):69-77. PubMed ID: 17959301
[TBL] [Abstract][Full Text] [Related]
14. Combined IFN-gamma-endostatin gene therapy and radiotherapy attenuates primary breast tumor growth and lung metastases via enhanced CTL and NK cell activation and attenuated tumor angiogenesis in a murine model.
Liu LL; Smith MJ; Sun BS; Wang GJ; Redmond HP; Wang JH
Ann Surg Oncol; 2009 May; 16(5):1403-11. PubMed ID: 19263173
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic effect of Active Hexose-Correlated Compound (AHCC) combined with CpG-ODN (oligodeoxynucleotide) in B16 melanoma murine model.
Ignacio RM; Kim CS; Kim YD; Lee HM; Qi XF; Kim SK
Cytokine; 2015 Dec; 76(2):131-137. PubMed ID: 26082022
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-4 and CpG oligonucleotide therapy suppresses the outgrowth of tumors by activating tumor-specific Th1-type immune responses.
Kajiwara A; Doi H; Eguchi J; Ishii S; Hiraide-Sasagawa A; Sakaki M; Omori R; Hiroishi K; Imawari M
Oncol Rep; 2012 Jun; 27(6):1765-71. PubMed ID: 22426807
[TBL] [Abstract][Full Text] [Related]
17. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances anti-tumor responses of peripheral blood mononuclear cells from human lung cancer patients.
Ren T; Wen ZK; Liu ZM; Qian C; Liang YJ; Jin ML; Cai YY; Xu L
Cancer Invest; 2008 Jun; 26(5):448-55. PubMed ID: 18568766
[TBL] [Abstract][Full Text] [Related]
18. CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations.
van Ojik HH; Bevaart L; Dahle CE; Bakker A; Jansen MJ; van Vugt MJ; van de Winkel JG; Weiner GJ
Cancer Res; 2003 Sep; 63(17):5595-600. PubMed ID: 14500400
[TBL] [Abstract][Full Text] [Related]
19. Synergistic effect of intratumoral IL-12 and TNF-alpha microspheres: systemic anti-tumor immunity is mediated by both CD8+ CTL and NK cells.
Sabel MS; Arora A; Su G; Mathiowitz E; Reineke JJ; Chang AE
Surgery; 2007 Nov; 142(5):749-60. PubMed ID: 17981196
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-28B acts synergistically with cisplatin to suppress the growth of head and neck squamous cell carcinoma.
Yoshimoto K; Kishida T; Nakano H; Matsui M; Shin-Ya M; Shimada T; Nakai S; Imanishi J; Takeuchi M; Hisa Y; Mazda O
J Immunother; 2011 Mar; 34(2):139-48. PubMed ID: 21304406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]